Products
Ferumoxytol is commercially available as a solution for intravenous injection (Rienso). It has been approved in many countries since 2012.
Structure and properties
Ferumoxytol is a colloidal iron-carbohydrate complex. It contains iron oxide particles with an iron oxide core surrounded by a shell of polyglucose sorbitol carboxymethyl ether.
Effects
The supplied iron substitutes for the amount of iron lacking in the body. On the one hand, it is used to build hemoglobin and thus red blood cells, myoglobin, and enzymes, and on the other hand, it is stored in the liver, for example. A deficit can thus be quickly compensated.
Indications
For treatment of iron deficiency in chronic kidney disease when oral therapy is not feasible.
Dosage
According to the SmPC. The drug is administered as an intravenous injection.
Contraindications
Ferumoxytol should not be administered in cases of hypersensitivity, evidence of iron overload, and anemia not caused by iron deficiency. For complete precautions, see the drug label.
Interactions
Ferumoxytol should not be combined with oral iron.
Adverse effects
The most common possible adverse effects include digestive symptoms such as diarrhea, constipation, nausea, and vomiting, as well as headache, dizziness, and hypotension.
